Citius Pharmaceuticals (NASDAQ:CTXR) Stock Price Down 3.1%

Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) were down 3.1% during mid-day trading on Wednesday . The company traded as low as $0.64 and last traded at $0.66. Approximately 1,675,141 shares traded hands during trading, an increase of 93% from the average daily volume of 867,677 shares. The stock had previously closed at $0.68.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 price target on shares of Citius Pharmaceuticals in a report on Wednesday, February 14th.

Citius Pharmaceuticals Trading Down 3.1 %

The firm has a market cap of $105.53 million, a PE ratio of -2.55 and a beta of 1.54. The stock has a fifty day simple moving average of $0.78 and a two-hundred day simple moving average of $0.76.

Citius Pharmaceuticals (NASDAQ:CTXR) last posted its earnings results on Wednesday, February 14th. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.19). As a group, sell-side analysts predict that Citius Pharmaceuticals, Inc. will post -0.21 earnings per share for the current fiscal year.

Institutional Trading of Citius Pharmaceuticals

Large investors have recently modified their holdings of the business. SG Americas Securities LLC bought a new stake in shares of Citius Pharmaceuticals during the 3rd quarter worth $39,000. Allspring Global Investments Holdings LLC bought a new stake in Citius Pharmaceuticals during the third quarter worth about $76,000. Wealth Advisory Solutions LLC purchased a new position in shares of Citius Pharmaceuticals in the 1st quarter worth about $135,000. Finally, BNP Paribas Financial Markets increased its position in shares of Citius Pharmaceuticals by 88.5% during the 1st quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock valued at $62,000 after purchasing an additional 32,686 shares during the last quarter. Institutional investors own 16.88% of the company’s stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.